SLQT — SelectQuote, Inc.

SelectQuote (SLQT) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Consolidated Revenue: $329 million, a 13% increase year-over-year.
• Senior Segment Revenue: $59 million, down from $93 million a year ago, attributed to lower policy production due to new eligibility rules.
• EBITDA: Consolidated EBITDA loss of $32 million, worse than the guided loss of $25 million to $30 million, primarily due to Healthcare Services margin pressures.
• Senior EBITDA: Negative $21 million, in line with expectations.
• Life Insurance Revenue: Grew nearly 20%, contributing positively to overall revenue.

2. Strategic Updates and Business Highlights

• Healthcare Services: The new Kansas facility is ramping up as planned, but first-quarter EBITDA was impacted by changes in drug reimbursement rates from a PBM partner, expected to affect Q1 and Q2.
• SelectRx: Emphasized the clinical value of SelectRx in improving medication adherence and health outcomes, with ongoing negotiations for a more stable reimbursement agreement.
• Agent Retention: Strong retention of tenured agents is expected to drive growth during the upcoming Medicare Advantage (MA) enrollment period.
• Focus on Retention: The company is prioritizing proactive communication with policyholders to improve understanding of their plans, which is expected to enhance retention rates.

3. Forward Guidance and Outlook

• Fiscal 2026 Revenue Guidance: Maintained at $1.65 billion to $1.75 billion.
• Adjusted EBITDA Guidance: $120 million to $150 million, though the target of $50 million for Healthcare Services is no longer anticipated due to the reimbursement headwind.
• Long-term Outlook: Confidence in achieving an annualized EBITDA run rate of $40 million to $50 million by the end of fiscal 2026, with expectations of being cash flow positive for the year.

4. Bad News, Challenges, or Points of Concern

• Senior Segment Decline: Significant drop in Senior segment revenue and policy production due to new eligibility requirements, leading to a negative EBITDA.
• Healthcare Services Headwinds: Changes in drug reimbursement rates are expected to impact profitability in the first half of fiscal 2026, with a $20 million hit anticipated in Q2.
• Market Volatility: The ongoing dynamic environment in the Medicare Advantage sector, with increased policyholder volatility and carrier focus on profitability, poses challenges for growth.

5. Notable Q&A Insights

• Reimbursement Concerns: Management expressed confidence in negotiating a favorable long-term agreement with the PBM partner despite current headwinds.
• LTV and Retention: While improvements in MA member retention due to SelectRx were noted, these benefits are not yet reflected in lifetime value calculations.
• AEP Season Outlook: Early indicators from the AEP season show strong consumer engagement and effective agent performance, with expectations for continued success despite market challenges.

In summary, SelectQuote reported solid revenue growth but faced challenges in its Senior segment and Healthcare Services due to regulatory changes and reimbursement issues. The company remains optimistic about its long-term strategy and upcoming enrollment seasons, while navigating near-term headwinds.